Literature DB >> 28797685

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer.

Neal Shore1, Axel Heidenreich2, Fred Saad3.   

Abstract

Optimal sequencing strategies for approved agents in metastatic castration-resistant prostate cancer (mCRPC) are unclear. Retrospective clinical studies suggest cross-resistance between specific therapies. This review assesses treatment decisions for mCRPC. Increased use of chemohormonal therapy in castration-sensitive disease may affect subsequent treatment decisions in mCRPC. Initial abiraterone or enzalutamide treatment may result in cross-resistance for subsequent androgen receptor-targeted therapy. Clinical responses may be seen in both docetaxel- and cabazitaxel-treated patients progressing after treatment with abiraterone or enzalutamide. These observations are supported by proposed resistance mechanisms. In conclusion, small, retrospective studies suggest cross-resistance between specific therapies in mCRPC. Larger prospective studies are required.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2017        PMID： 28797685     DOI： 10.1016/j.urology.2017.04.062

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  7 in total

1.  Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY.

Authors:  Scott T Tagawa; Emmanuel S Antonarakis; Ada Gjyrezi; Giuseppe Galletti; Seaho Kim; Daniel Worroll; John Stewart; Atef Zaher; Ted P Szatrowski; Karla V Ballman; Katsuhiro Kita; Shinsuke Tasaki; Yang Bai; Luigi Portella; Brian J Kirby; Fred Saad; Mario A Eisenberger; David M Nanus; Paraskevi Giannakakou
Journal:  Clin Cancer Res       Date:  2018-10-09       Impact factor: 12.531

2.  Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).

Authors:  Fred Saad; Kim N Chi; Neal D Shore; Julie N Graff; Edwin M Posadas; Jean-Baptiste Lattouf; Byron M Espina; Eugene Zhu; Alex Yu; Anasuya Hazra; Marc De Meulder; Rao N V S Mamidi; Branislav Bradic; Peter Francis; Vinny Hayreh; Arash Rezazadeh Kalebasty
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-22       Impact factor: 3.333

3.  Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.

Authors:  Serban Negoita; Eric J Feuer; Angela Mariotto; Kathleen A Cronin; Valentina I Petkov; Sarah K Hussey; Vicki Benard; S Jane Henley; Robert N Anderson; Stacey Fedewa; Recinda L Sherman; Betsy A Kohler; Barbara J Dearmon; Andrew J Lake; Jiemin Ma; Lisa C Richardson; Ahmedin Jemal; Lynne Penberthy
Journal:  Cancer       Date:  2018-05-22       Impact factor: 6.860

4.  177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians.

Authors:  Ting Bu; Lulu Zhang; Fei Yu; Xiaochen Yao; Wenyu Wu; Pengjun Zhang; Liang Shi; Shiming Zang; Qingle Meng; Yudan Ni; Guoqiang Shao; Xuefeng Qiu; Shuyue Ai; Ruipeng Jia; Hongqian Guo; Feng Wang
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

Review 5.  Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.

Authors:  Shiv Verma; Kumari Sunita Prajapati; Prem Prakash Kushwaha; Mohd Shuaib; Atul Kumar Singh; Shashank Kumar; Sanjay Gupta
Journal:  Cancer Drug Resist       Date:  2020-09-17

6.  Radium-223 for metastatic castration-resistant prostate cancer: results and remaining open issues after the ALSYMPCA trial.

Authors:  Isabel Heidegger; Renate Pichler; Axel Heidenreich; Wolfgang Horninger; Andreas Pircher
Journal:  Transl Androl Urol       Date:  2018-03

Review 7.  The use of long non-coding RNAs as prognostic biomarkers and therapeutic targets in prostate cancer.

Authors:  Cristian Arriaga-Canon; Inti Alberto De La Rosa-Velázquez; Rodrigo González-Barrios; Rogelio Montiel-Manríquez; Diego Oliva-Rico; Francisco Jiménez-Trejo; Carlo Cortés-González; Luis A Herrera
Journal:  Oncotarget       Date:  2018-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.